Sensitive multiple myeloma disease monitoring by mass spectrometry

Santockyte, Rasa; Jin, Chelsea; Pratt, James; Ammar, Ron; Desai, Keyur; Bolisetty, Mohan; Das, Prianka; Popa-McKiver, Mihaela; Puig, Óscar

doi:10.1038/s41408-021-00473-9

Cited by 9 publications

(10 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Once the M-protein is cleared, mass spectrometry shows promise for detecting early relapse. In two separate studies, LC-HRMS detected an increase in the M-protein concentration months earlier than standard analysis [9,21].…”

Section: Minimal Residual Disease (Mrd)mentioning

confidence: 94%

“…The limit of detection of mass spectrometry assays ranges from about 0.05 to 0.001 g/dL and largely depends on type of mass spectrometer used. The clinical utility of these mass spectrometry assays is being evaluated at all stages of disease: screening and diagnosis [12][13][14], routine monitoring [12,15], assessment of minimal residual disease (MRD) [11,[16][17][18][19][20], and detection of relapse [9,21,22].…”

Section: Mass Spectrometry Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Will Mass Spectrometry Replace Current Techniques for Both Routine Monitoring and MRD Detection in Multiple Myeloma?

Thoren

2021

Hemato

View full text Add to dashboard Cite

In recent years, mass spectrometry has been increasingly used for the detection of monoclonal proteins in serum. Mass spectrometry is more analytically sensitive than serum protein electrophoresis and immunofixation, can help distinguish therapeutic monoclonal antibodies from M-proteins, and can detect the presence of post-translational modifications. Mass spectrometry also shows promise as a less-invasive, peripheral-blood-based test for detecting minimal residual disease in multiple myeloma. Studies comparing the clinical utility of mass spectrometry to current blood- and bone-marrow-based techniques have been conducted. Although still primarily limited to research settings, clinical laboratories are starting to adopt this technique for patient care. This review will discuss the current status of mass spectrometry testing for multiple myeloma, the benefits and challenges of this technique, and how it may be incorporated into clinical practice in the future.

show abstract

Section: Minimal Residual Disease (Mrd)mentioning

confidence: 94%

Section: Mass Spectrometry Methodsmentioning

confidence: 99%

Will Mass Spectrometry Replace Current Techniques for Both Routine Monitoring and MRD Detection in Multiple Myeloma?

Thoren

2021

Hemato

View full text Add to dashboard Cite

show abstract

“…The minimally invasive technology mass spectrometry (MS), which is amenable to automation, is emerging as a promising approach for detecting and monitoring monoclonal proteins in the peripheral blood (PB) [5][6][7][8][9]. MS has been shown to be superior to standard electrophoretic methods for the detection of monoclonal immunoglobulins, such as serum immunofixation (IFE) [10][11][12][13]. Furthermore, recent data suggests a role for MS as a complementary approach for the detection of minimal residual disease (MRD) [11,13], overcoming the limitations of bone marrow-based methods for identifying systemic disease.…”

Section: Introductionmentioning

confidence: 99%

“…MS has been shown to be superior to standard electrophoretic methods for the detection of monoclonal immunoglobulins, such as serum immunofixation (IFE) [10][11][12][13]. Furthermore, recent data suggests a role for MS as a complementary approach for the detection of minimal residual disease (MRD) [11,13], overcoming the limitations of bone marrow-based methods for identifying systemic disease.…”

Section: Introductionmentioning

confidence: 99%

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

et al. 2023

View full text Add to dashboard Cite

Mass spectrometry (MS) is a promising tool for monitoring monoclonal protein in plasma cell dyscrasias. We included 480 transplant-eligible newly-diagnosed multiple myeloma (MM) patients from the GMMG-MM5 trial (EudraCT No. 2010-019173-16) and performed a retrospective MS analysis at baseline (480 patients) and at the pre-defined, consecutive time points after induction (444 patients), prior to maintenance (305 patients) and after one year of maintenance (227 patients). We found that MS negativity was significantly associated with improved progression-free survival (PFS) even in patients with complete response (CR) at all investigated follow-up time points. The prognostic impact was independent of established risk factors, such as the revised International Staging System. Combining MS and baseline cytogenetics improved the prediction of outcome: MS-positive patients with high-risk cytogenetics had a dismal PFS of 1.9 years (95% confidence interval [CI]: 1.6–2.3 years) from the start of maintenance. Testing the value of sequential MS prior to and after one year of maintenance, patients converting from MS positivity to negativity had an excellent PFS (median not reached) while patients converting from MS negativity to positivity progressed early (median 0.6 years, 95% CI: 0.3-not reached). Among patients with sustained MS positivity, the baseline high-risk cytogenetic status had a significant impact and defined a group with poor PFS. Combining minimal residual disease (MRD) in the bone marrow and MS allowed the identification of double negative patients with a favorable PFS (median 3.33 years, 95% CI: 3.08-not reached) and no overall survival events. Our study provides strong evidence that MS is superior to conventional response monitoring, highlighting the potential of MS to become a new standard. Our data indicate that MS should be performed sequentially and combined with baseline disease features and MRD to improve its clinical value.Clinical Trials Register: EudraCT No. 2010-019173-16

show abstract

“… 6 With mass spectrometry (MS), it is possible to monitor M-proteins in blood in a more sensitive manner than with SPEP. 7 - 9 …”

mentioning

confidence: 99%

Retrospective Longitudinal Monitoring of Multiple Myeloma Patients by Mass Spectrometry Using Archived Serum Protein Electrophoresis Gels and De Novo Sequence Analysis

et al. 2022

View full text Add to dashboard Cite

Sensitive multiple myeloma disease monitoring by mass spectrometry

Cited by 9 publications

References 9 publications

Will Mass Spectrometry Replace Current Techniques for Both Routine Monitoring and MRD Detection in Multiple Myeloma?

Will Mass Spectrometry Replace Current Techniques for Both Routine Monitoring and MRD Detection in Multiple Myeloma?

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

Retrospective Longitudinal Monitoring of Multiple Myeloma Patients by Mass Spectrometry Using Archived Serum Protein Electrophoresis Gels and De Novo Sequence Analysis

Contact Info

Product

Resources

About